Main Article Content


M.K. Imanbekova

National Center for Biotechnology, 13/5, Korgalzhyn road, Astana,010000, Kazakhstan

G.S. Stybayeva

National Center for Biotechnology, 13/5, Korgalzhyn road, Astana,010000, Kazakhstan
Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 1stStreet SW, St-11-14, Rochester, MN, 55905

A. Revzin

Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 1stStreet SW, St-11-14, Rochester, MN, 55905

E.V. Zholdybaeva

National Center for Biotechnology, 13/5, Korgalzhyn road, Astana,010000, Kazakhstan


Aptamers are synthetic nucleic acids developed to bind specific targets, such as amino acids, drugs, proteins, and other molecules. In nature, aptamers exist as riboswitches, which are genetic regulatory elements. Aptamers can be generated using a method called SELEX, an iterative process of adsorption, separation, and amplification, followed by sequencing of a specific oligonucleotide. The entire SELEX process takes between a week to a month to complete and consists of 8–20 rounds. Aptamers are an excellent alternative to monoclonal antibodies, which are expensive and immunogenic. Advantages that aptamers offer over antibodies include stability, low cost, lack of toxicity and immunogenicity, minimized batch-to-batch variation, and the ability to develop them against a variety of targets. The ease in which aptamers can be synthesised and modified allow for the creation and application of aptamers for use in various fields of biology and medicine, including diagnostics, targeted drug delivery, discovery of new biomarkers, biovisualization, and molecular therapy.


aptamer, SELEX, aptasensors, diagnostics, targeted delivery, bioimaging

Article Details


Chopra A., Shukla R., Sharma T. K. Aptamers as an emerging player in biology. Aptamers Syn Antibodies, 2014, vol. 1, no. 1, pp. 1-11.

Sun H., Zu Y. A highlight of recent advances in aptamer technology and its application, Molecules, 2015, vol. 20, no. 7, pp. 11959-11980.

Nimjee S.M. et al. Aptamers as therapeutics. Annual review of pharmacology and toxicology,2017, vol. 57, pp. 61-79.

Mairal T. et al. Aptamers: molecular tools for analytical applications. Analytical and bioanalytical chemistry, 2008, vol. 390, no. 4, pp. 989-1007.

Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands.Nature, 1990, vol. 346, no. 6287, pp. 818.

Tuerk C. et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, vol. 249, no. 4968, pp. 505-510.

Riley K.R. et al. Combining capillary electrophoresis and next-generation sequencing for aptamer selection. Analytical and bioanalytical chemistry, 2015, vol. 407, no. 6, pp. 1527.

Stoltenburg R., Reinemann C., Strehlitz B. SELEX - a (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomolecular engineering, 2007, vol. 24, no. 4, pp. 381-403.

Khati M. et al. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′ F-RNA aptamers. Journal of virology, 2003, vol. 77, no. 23, pp. 12692-12698.

Kedzierski S., Khoshnejad M., Caltagirone G.T. Synthetic antibodies: the emerging field of aptamers. Bioprocessing J, 2012, vol. 11, pp. 46-49.

Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nature reviews Drug discovery, 2010, vol. 9, vol. 7, pp. 537-550.

Sharma T.K., Bruno J.G., Dhiman A. ABCs of DNA aptamer and related assay development. Biotechnology advances, 2017.

Morris K.N. et al. High affinity ligands from in vitro selection: complex targets. Proceedings of the National Academy of Sciences, 1998, vol. 95, no. 6, pp. 2902-2907.

Feng C., Dai S., Wang L. Optical aptasensors for quantitative detection of small biomolecules: A review. Biosensors and Bioelectronics, 2014, vol. 59, pp. 64-74.

Abnous K. et al. A new amplified π-shape electrochemical aptasensor for ultrasensitive detection of aflatoxin B 1.Biosensors and Bioelectronics, 2017, vol. 94.pp. 374-379.

Smolinska-Kempisty K. et al. New potentiometric sensor based on molecularly imprinted nanoparticles for cocaine detection. Biosensors and Bioelectronics, 2017, vol. 96, pp. 49-54.

Li Q. et al. Ultrasensitive detection of aflatoxin B 1 by SERS aptasensor based on exonuclease-assisted recycling amplification. Biosensors and Bioelectronics, 2017, vol. 97, pp. 59-64.

Lee A.Y. et al. Development of a ssDNA aptamer for detection of residual benzylpenicillin. Analytical biochemistry, 2017, vol. 531, pp. 1.

Ruscito A., DeRosa M.C. Small-molecule binding aptamers: Selection strategies, characterization, and applications. Frontiers in chemistry, 2016, vol. 4.

Park J.H. et al. A highly sensitive and widely adaptable plasmonicaptasensor using berberine for small-molecule detection.Biosensors and Bioelectronics, 2017.

Hianik T., Wang J. Electrochemical aptasensors–recent achievements and perspectives. Electroanalysis, 2009, vol. 21, no. 11, pp. 1223-1235.

Sassolas A., Blum L.J., Leca‐Bouvier B.D. Electrochemical aptasensors. Electroanalysis, 2009, vol. 21, no. 11, pp. 1237-1250.

Tabasi A., Noorbakhsh A., Sharifi E. Reduced graphene oxide-chitosan-aptamer interface as new platform for ultrasensitive detection of human epidermal growth factor receptor 2. Biosensors and Bioelectronics, 2017, vol. 95, pp. 117-123.

Wang J. et al. RNA aptamer-based electrochemical aptasensor for C-reactive protein detection using functionalized silica microspheres as immunoprobes.Biosensors and Bioelectronics, 2017, vol. 95, pp. 100-105.

Zhou Q. et al. Development of an aptasensor for electrochemical detection of exosomes. Methods, 2016, vol. 97, pp. 88-93.

Matharu Z. et al. Detecting transforming growth factor-β release from liver cells using an aptasensor integrated with microfluidics. Analytical chemistry, 2014, vol. 86, no. 17, pp. 8865-8872.

Enomoto J., Matharu Z., Revzin A. Electrochemical biosensors for on-chip detection of oxidative stress from cells. Method Enzymol, 2013, vol. 526, pp. 107-121.

Liu Y., Zhou Q., Revzin A. An aptasensor for electrochemical detection of tumor necrosis factor in human blood.Analyst, 2013, vol. 138, no. 15, pp. 4321-4326.

Malvano F. et al. A new label-free impedimetricaptasensor for gluten detection.Food Control, 2017, vol. 79, pp. 200-206.

Luo Y. et al. Rapid and simultaneous quantification of 4 urinary proteins by piezoelectric quartz crystal microbalance immunosensor array.Clinical Chemistry, 2006, vol. 52, no. 12, pp. 2273-2280.

Zhang B. et al. A novel piezoelectric quartz micro-array immunosensor based on self-assembled monolayer for determination of human chorionic gonadotropin. Biosensors and Bioelectronics, 2004, vol. 19, no. 7, pp. 711-720.

Yao C. et al. Development of a quartz crystal microbalance biosensor with aptamers as bio-recognition element. Sensors, 2010, vol. 10, no. 6, pp. 5859-5871.

Dollins C.M., Nair S., Sullenger B.A. Aptamers in immunotherapy. Human gene therapy, 2008, vol. 19, no.5, pp. 443-450.

Sullenger B.A. et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 1990, vol. 63, no. 3, pp. 601-608.

O'Malley R.P. et al. A mechanism for the control of protein synthesis by adenovirus VA RNAI.Cell, 1986, vol.44, no. 3, pp. 391-400.

Burgert H.G. et al. Subversion of host defense mechanisms by adenoviruses.Viral Proteins Counteracting Host Defenses. – Springer Berlin Heidelberg, 2002, pp. 273-318.

Knöbl P. et al. Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion, 2009, vol. 49, no. 10, pp. 2181-2185.

Pietras K. et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer research, 2002, vol. 62, no. 19, pp. 5476-5484.

Ni X. et al. Nucleic acid aptamers: clinical applications and promising new horizons. Current medicinal chemistry, 2011, vol. 18, no. 27, pp. 4206-4214.

Khati M. et al. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′ F-RNA aptamers. Journal of virology, 2003, vol. 77, vol. 23, pp. 12692-12698.

de Campos W.R.L. et al. Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrobial agents and chemotherapy, 2009, vol. 53, no. 7, pp. 3056-3064.

Jeon S. H. et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. Journal of Biological Chemistry, 2004, vol. 279, no. 46, pp. 48410-48419.

Davydova A. et al. Aptamers against pathogenic microorganisms.Critical reviews in microbiology, 2016, vol. 42, no. 6, pp. 847-865.

Cao X. et al. Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus.Nucleic acids research, 2009, vol. 37, no. 14, pp. 4621-4628.

Waters E.K. et al. Effect of NU172 and bivalirudin on ecarin clotting time in human plasma and whole blood. Journal of Thrombosis and Haemostasis, 2009, vol. 7, pp. 683.

Oney S. et al. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides, 2007, vol. 17, no. 3, pp. 265-274.

Ishiguro A. et al. Therapeutic potential of anti–interleukin17A aptamer: Suppression of interleukin17A signaling and attenuation of autoimmunity in two mouse models. Arthritis & Rheumatology, 2011, vol. 63, no. 2, pp. 455-466.

Subramanian N. et al. Chimeric nucleolin aptamer with survivinDNAzyme for cancer cell targeted delivery. Chemical Communications, 2015, vol. 51, no. 32, pp. 6940-6943.

Cao Z. et al. Reversible cell‐specific drug delivery with aptamer‐functionalized liposomes.AngewandteChemie International Edition, 2009, vol. 48, no. 35, pp. 6494-6498.

Mankoff D.A. A definition of molecular imaging.Journal of Nuclear Medicine, 2007, vol. 48, no. 6, pp. 18N-21N.

Hong H. et al. Molecular imaging with nucleic acid aptamers.Current medicinal chemistry, 2011, vol. 18, no. 27, pp. 4195-4205.

Charlton J., Sennello J., Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase.Chemistry & biology, 1997, vol. 4, no. 11, pp. 809-816.

Varmira K. et al. A HER2-targeted RNA aptamer molecule labeled with 99m Tc for single-photon imaging in malignant tumors. Nuclear medicine and biology, 2013, vol. 40, no, 8, pp. 980-986.

Kim D., Jeong Y.Y., Jon S. A drug-loaded aptamer−gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.ACS nano, 2010, vol. 4, no. 7, pp. 3689-3696.

Nucleic acid aptamers for diagnostics and therapeutics. Global Markets.Available at:URL.